preparing a vector specific to said type of cancerous cells comprising an expression control sequence operatively linked to the nucleic acid sequence of a mammalian PP2Ca gene, said vector being capable of targeting said cancerous cells; and administering to the patient a therapeutically effective amount of a composition comprising said vector as an active ingredient, thereby

Ponda

## Please add new claims 68-76 as follows:

treating the cancer in the patient.

68. The method of claim 65 wherein said mammalian PP2Cα gene comprises a human PP2Cα/gene.

- 69. A method of introducing a vector into cancerous cells, comprising:
  - (a) detecting a type of cancerous cells in the patient wherein a decrease in PP2Cα gene activity is detected;
  - (b) preparing a vector specific to the cancerous cells comprising an expression control sequence operatively linked to the nucleic acid sequence of mammalian PP2Cα, said vector being capable of targeting said cancerous cells; and
  - (c) introducing said vector into said cancerous cells.
- 70. The method of claim 69 wherein the mammalian PP2Cα gene comprises a human PP2Cα gene.

71. The method of claim 69 performed according to stable transfection, trans

The method of claim 69, wherein said introducing of said vector is performed according to a method selected from the group consisting of stable transfection, transient transfection, lipofection, electroporation and infection with a recombinant viral vector.

72. The method according to claim 69 wherein said vector includes at least one targetor moiety.

The method according to claim 72 wherein said targetor moiety is a receptor.

The method according to claim 72 wherein said targetor moiety is a ligand.

The method according to claim 69 wherein PP2Ca gene activity is defined by assaying mRNA complementary to PP2Ca DNA including polymorphisms thereof in the cells with an assay selected from the group consisting of in situ hybridization, Northern blotting and reverse transcriptase – polymerase chain reaction.

The method according to claim 69 wherein said PP2Ca gene activity is defined by assaying PP2Ca gene product in said cells with an assay